PMID- 8231242
OWN - NLM
STAT- MEDLINE
DCOM- 19931210
LR  - 20181130
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 7
IP  - 11
DP  - 1993 Nov
TI  - Restoration of impaired cytokine secretion from monocytes of patients with 
      myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3.
PG  - 1728-33
AB  - Cytokine treatment in patients with myelodysplastic syndrome (MDS) aims to 
      overcome the maturation defects of myeloid lineage cells associated with 
      cytopenia and cellular dysfunction of mature cells. Since phagocytes play a major 
      role in host defense against microbial infection, we investigated cytokine 
      secretion and oxygen radical release (ORR) from peripheral blood monocytes (PBMC) 
      in a total of 16 MDS patients, 12 patients with refractory anemia (RA) and four 
      patients with RA and excess of blasts (RAEB). Interleukin (IL-6), tumour necrosis 
      factor alpha (TNF alpha), IL-1 beta, and IL-8 secretion from monocytes in 
      response to lipopolysaccharide (LPS) was significantly reduced in the 12 patients 
      with RA compared to 12 healthy controls, whereas no difference was seen in ORR. 
      We further assessed cytokine secretion from monocytes of 10 MDS patients before 
      and after therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), 
      IL-3, or a combination therapy with GM-CSF and cytosine arabinoside (AraC). In 
      all 10 patients, secretion of IL-1 beta, IL-6, and TNF alpha from PBMC increased 
      after cytokine therapy, whereas IL-8 secretion increased only in five patients 
      with GM-CSF or IL-3 therapy receiving a dosage > or = 250 micrograms/m2 per day 
      but decreased in all other patients. ORR increased in all patients on either 
      GM-CSF or IL-3 therapy. These data indicate that the ability of monocytes to 
      secrete secondary cytokines is impaired in MDS patients but can be restored by in 
      vivo administration of GM-CSF and IL-3.
FAU - Maurer, A B
AU  - Maurer AB
AD  - Department of Haematology, University of Frankfurt, Germany.
FAU - Ganser, A
AU  - Ganser A
FAU - Buhl, R
AU  - Buhl R
FAU - Seipelt, G
AU  - Seipelt G
FAU - Ottmann, O G
AU  - Ottmann OG
FAU - Mentzel, U
AU  - Mentzel U
FAU - Geissler, R G
AU  - Geissler RG
FAU - Hoelzer, D
AU  - Hoelzer D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Cytokines)
RN  - 0 (Free Radicals)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-3)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aged
MH  - Cytokines/*metabolism
MH  - Female
MH  - Free Radicals
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use
MH  - Humans
MH  - Interleukin-1/metabolism
MH  - Interleukin-3/*therapeutic use
MH  - Interleukin-6/metabolism
MH  - Interleukin-8/metabolism
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*metabolism
MH  - Myelodysplastic Syndromes/blood/*therapy
MH  - Oxygen/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - Leukemia. 1993 Nov;7(11):1728-33.